## PAIRNT COOPERATION TREATY





(PCT Article 18 and Rules 43 and 44)

Applicant's or agent's file reference 540618101WO	FOR FURTHER ACTION	(Form PC) below.	ation of Transmittal of International Search Report [/ISA/220] as well as, where applicable, item 5  [(Earliest) Priority Date (day/month/year)				
International application No. PCT/US03/18657	International filing date (day/month/year) 13 June 2003 (13.06.2003)		14 June 2002 (14.06.2002)				
Applicant AMYLIN PHARMACEUTICALS, IN C							
This international search report has be applicant according to Article 18. A c	opy is being umaning	Searching a ternational	Authority and is transmitted to the Bureau.				
This international search report consis	ed by a copy of each prior art do	ument cite	ed in this report.				
			he basis of the international application in the				
a. With regard to the language, the international application furnished to this language in which it was filed, unless otherwise indicated under this item.  the international search was carried out on the basis of a translation of the international application furnished to this							
Authority (Rule 23.1(b)).  b. With regard to any nucleotide and/or amino acid sequence disclosed in the international application, the international search was carried out on the basis of the sequence listing:							
contained in the internation	onal application in written form.						
filed together with the in	filed together with the international application in computer readable form.						
furnished subsequently to	this Authority in written form.						
C istand subsequently to	this Authority in computer readab	le form.					
the statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the							
international application as fired has been remarked.  the statement that the information recorded in computer readable form is identical to the written sequence listing has been furnished.							
2. Certain claims were for	Certain claims were found unsearchable (See Box I).						
3. Unity of invention is la			·				
4. With regard to the title,							
the text is approved as s	the text is approved as submitted by the applicant.						
the text has been establi	ished by this Authority to read as fo	ollows:					
5. With regard to the abstract,	submitted by the applicant.						
	the text is approved as submitted by the applicant.  the text is approved as submitted by the applicant.  the text has been established, according to Rule 38.2(b), by this Authority as it appears in Box III. The applicant the text has been established, according to Rule 38.2(b), by this Authority as it appears in Box III.						
the text has been estable may, within one month Authority.	from the date of mailing of this in	ternational	search report, submit comments to this				
6. The figure of the drawings to	be published with the abstract is Fi	gure No					
as suggested by the ap	plicant.		None of the figures				
	failed to suggest a figure.						
	ter characterizes the invention.						
Domina (210 (first sheet) (July							

Form PCT/ISA/210 (first sheet) (July 1998)

## INTERNATIONAL SEARCH REPORT

International application No.
JS03/18657

Box I Observations where certain claims were found unsearchable (Continuation of Item 1 of first sheet)					
This international report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:					
1. Claim Nos.: because they relate to subject matter not required to be searched by this Authority, namely:					
2. Claim Nos.:  because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:					
3. Claim Nos.:  because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).					
Box II Observations where unity of invention is lacking (Continuation of Item 2 of first sheet)					
This International Searching Authority found multiple inventions in this international application, as follows: Please See Continuation Sheet					
<ol> <li>As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.</li> <li>As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.</li> <li>As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:</li> </ol>					
4. No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.: 1-4 and 19-22  Remark on Protest					

Form PCT/ISA/210 (continuation of first sheet(1)) (July 1998)

A. CLASSIFICATION OF SUBJECT MATTER  IPC(7) : A61K 38/16; 31/00  US CL								
US CL: 424/198.1; 514/1 According to International Patent Classification (IPC) or to both national classification and IPC								
B. FIELDS SEARCHED								
Minimum documentation searched (classification system followed by classification symbols) U.S.: 424/198.1; 514/1								
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched								
Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) EAST, STN/BIOSIS, MEDLINE								
C. DOC	UMENTS CONSIDERED TO BE RELEVANT							
Category *	Citation of document, with indication, where a	ppropriate, of the relevant passages	Relevant to claim No.					
x	EL-SALHY et al, Peptide YY in gastrointestinal di		1-4					
 Y	pages 397-402, especially abstract, pages 398-399,	pages 397-402, especially abstract, pages 398-399, and 401.						
x 	US 5,604,203 A (Balasubramaniam, A.) 18 Februa	ry 1997 (18.02.1997), column 7.	1, 2, 4					
Y			3, 19-22					
 Y	DUMONT et al, Peptide YY derivatives as selective Y2 agonists devoided of activity for the Y3 receptor October 1994, Vol. 26, Issue 1-2, pages 320-324, or 1994.	19-22						
		·						
Further	documents are listed in the continuation of Box C.	See patent family annex.						
Special categories of cited documents:  "A" document defining the general state of the art which is not considered to		"T" later document published after the in priority date and not in conflict with understand the principle or theory un	the application but cited to					
"E" earlier application or patent published on or after the international filing co		"X" document of particular relevance; the considered novel or cannot be considered when the document is taken along the considered when the document is taken along the considered with the constant of the co	dered to involve an inventive					
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)		"Y" document of particular relevance; the considered to involve an inventive st combined with one or more other su combination being obvious to a pers	tep when the document is ch documents, such					
	t referring to an oral disclosure, use, exhibition or other means	"&" document member of the same paten	t family					
"P" document published prior to the international filing date but later than the priority date claimed								
Date of the a	actual completion of the international search	Date of mailing of the international search report  9 9 ADD 2004						
	2004 (29.02.2004)	Authorized officer						
l .	ailing address of the ISA/US il Stop PCT, Aun: ISA/US	Authorized officer	11 // 1 lat					
Cor	nmissioner for Patents	Ruixiang Li	LAUNU AN					
P.O. Box 1450 Alexandria, Virginia 22313-1450 Telephone No. (703) 308-0196								
Facsimile No. (703) 305-3230								
Form PCT/ISA/210 (second sheet) (July 1998)								

## INTERNATIONAL SEARCH REPORT



## BOX II. OBSERVATIONS WHERE UNITY OF INVENTION IS LACKING

The inventions listed as Groups I-V do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons:

- (i) The methods of Groups I-III are distinct methods, each having completely different method steps, using different compositions and having completely different outcomes; whereas Groups IV and V are drawn to two entirely different products, a composition comprising a PYY molecule or a PYY agonist and a probiotic baterium, respectively.
- (ii) The special technical features of Groups I-III are a method of treating a bowel condition comprising administering a pharmaceutically active formulation of PYY or a PYY agonist to a patient, a method of identifying a PYY agonist useful for the prevention or treatment of a bowel condition, and a method of identifying a PYY agonist useful for the prevention or treatment of a bowel condition, respectively, whereas the special technical features in Groups IV and V are a composition comprising a PYY molecule or an agonist of PYY molecule, and a probiotic bacterium comprising a nucleic acid encdoing PYY or a PYY agonist, respectively. Since none of the special technical features of the Groups I-V is found in more than one of the inventions, unity of invention is lacking.

Accordingly, Groups I-V are not so linked by the same or a corresponding special technical feature as to form a single general concept.

2. In the absence of any response from the Applicant, this Authority will establish the International Preliminary Search Report based on the main invention. The claims drawn to the main invention are as follows:

Claims 1-4 and 19-22.

- I. Claims 1-4, and 19-22, drawn to a method of treating a bowel condition comprising administering a pharmaceutically active formulation of PYY or a PYY agonist to a patient.
- II. Claims 5-8, 23, and 24, drawn to a method of manufacturing a drug priduct comprising PYY or an agonist of PYY.
- III. Claims 9 and 10, drawn to a method of identifying a PYY agonist useful for the prevention or treatment of a bowel condition.
- IV. Claims 11-13, 16-18, and 25, drawn to a composition comprising a PYY molecule or an agonist of PYY molecule.
- V. Claims 14 and 15, drawn to a probiotic bacterium comprising a nucleic acid encdoing PYY or a PYY agonist.

	INTERNATIO	NAU SEARCH R	EFORI	
	<del></del>			1
			. •	
·				
			·	
	,			
			·	
	·			
1		•		
		·	•	

Form PCT/ISA/210 (second sheet) (July 1998)

PCT/US03/18657